Matrix metalloproteinases inhibitors in idiopathic pulmonary fibrosis: Medicinal chemistry perspectives.

Abstract

Idiopathic pulmonary fibrosis (IPF) is a lethal disease with limited therapeutic options and a particularly poor prognosis. Matrix metalloproteinases (MMPs), promising targets for the treatment of IPF, have been identified as playing a pivotal role in IPF. Although the pathological processes of MMPs and IPF have been verified, there are no MMP inhibitors for the treatment of IPF in the clinic. In this review, we will present the latest developments in MMP inhibitors, including pharmacophores, binding modes, selectivity and optimization strategies. In addition, we will also discuss the future development direction of MMP inhibitors based on emerging tools and techniques.

• Authors: Lin Yue, Yaojie Shi, Xingping Su, Liang Ouyang, Guan Wang, Tinghong Ye
• Journal: European journal of medicinal chemistry (Eur J Med Chem) Vol. 224 Pg. 113714 (Nov 15 2021) ISSN: 1768-3254 [Electronic] France
• PMID: 34315043 (Publication Type: Journal Article)
• Copyright: Copyright © 2021 Elsevier Masson SAS. All rights reserved.

Chemical References

• Matrix Metalloproteinase Inhibitors

Topics

• Chemistry, Pharmaceutical
• Humans
• Idiopathic Pulmonary Fibrosis (drug therapy)
• Matrix Metalloproteinase Inhibitors (pharmacology, therapeutic use)
• Models, Molecular
• Prognosis